Zhu Xin-Jie, Lu Mei-Ping, Chen Ruo-Xi, Mao Ze-Fan, Yang Yi-Fan, Han Jie, Cheng Lei
Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
Department of Otorhinolaryngology, Jiangsu Province Official Hospital & Geriatric Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
J Asthma Allergy. 2025 Jan 6;18:1-12. doi: 10.2147/JAA.S496020. eCollection 2025.
Although periostin has recently emerged as a new mediator in chronic allergic diseases, particularly in upper airway disease, its significance as a biomarker for allergic rhinitis (AR) is still unclear. Therefore, we aimed to assess the potential of periostin as a novel candidate biomarker for diagnosing and assessing the severity of AR.
A total of 40 patients with AR and 22 healthy controls, all aged over 18 years, were recruited for the study. Participants underwent examinations to assess serum levels of total IgE (tIgE), specific IgE (sIgE), periostin, and remodeling-related factors, as well as fractional exhaled nitric oxide (FeNO) and fractional nasal nitric oxide (FnNO). Additionally, clinical characteristics questionnaire and nasal function assessments were completed by AR patients.
The levels of serum periostin were significantly higher in patients with AR compared to healthy controls (Z=-3.605, <0.001). There was a notable positive correlation between serum periostin and FeNO (r=0.398, =0.012), FnNO (r=0.379, =0.017), as well as the visual analogue scale (VAS) score for ocular tearing (r=0.351, =0.026) in AR patients. Furthermore, the serum periostin levels were higher in moderate-to-severe AR compared to mild AR cases (Z=-2.007, =0.045). The level of serum periostin in AR patients showed a sequential increase corresponding to shortness of breath scores from 0 to 3 (Z=10.137, =0.017). The predicted probability of serum periostin demonstrated moderate diagnostic accuracy in detecting AR (AUC=0.773, <0.001).
Serum periostin shows potential as a candidate biomarker for detecting AR and can serve as a surrogate biomarker for assessing airway inflammation in AR patients.
尽管骨膜蛋白最近已成为慢性过敏性疾病，尤其是上呼吸道疾病中的一种新介质，但其作为变应性鼻炎（AR）生物标志物的意义仍不明确。因此，我们旨在评估骨膜蛋白作为诊断和评估AR严重程度的新型候选生物标志物的潜力。
本研究共招募了40例AR患者和22名健康对照者，所有参与者年龄均超过18岁。参与者接受了检查，以评估血清总IgE（tIgE）、特异性IgE（sIgE）、骨膜蛋白和重塑相关因子的水平，以及呼出一氧化氮分数（FeNO）和鼻腔一氧化氮分数（FnNO）。此外，AR患者完成了临床特征问卷和鼻功能评估。
与健康对照者相比，AR患者血清骨膜蛋白水平显著更高（Z=-3.605，P<0.001）。AR患者血清骨膜蛋白与FeNO（r=0.398，P=0.012）、FnNO（r=0.379，P=0.017）以及眼部流泪视觉模拟量表（VAS）评分（r=0.351，P=0.026）之间存在显著正相关。此外，中重度AR患者的血清骨膜蛋白水平高于轻度AR患者（Z=-2.007，P=0.045）。AR患者血清骨膜蛋白水平随呼吸急促评分从0到3呈逐步升高（Z=10.137，P=0.017）。血清骨膜蛋白的预测概率在检测AR方面显示出中等诊断准确性（AUC=0.773，P<0.001）。
血清骨膜蛋白显示出作为检测AR的候选生物标志物的潜力，并且可以作为评估AR患者气道炎症的替代生物标志物。
